民族医药
Search documents
德良方药业七条生产线满负荷运转
Xin Lang Cai Jing· 2026-01-25 22:24
转自:贵州日报 本报讯(记者 支太檾)1月25日,记者走进位于黔西南州兴义市的贵州德良方药业股份有限公司,药香 弥漫,机器轰鸣,繁忙有序的开年新气象扑面而来。 生产线上,胶囊缓缓流动、填充、封装。"公司7条生产线全部满负荷运转,全力保障节前订单交 付。"生产总监戴滔穿梭其中介绍,临近春节,呼吸类产品需求大增,消炎止咳胶囊日产量达8万盒,半 枝莲胶囊达4万盒。 企业订单簿上,"开年即冲刺"的忙碌清晰可见。公司副总经理黄河透露,订单总额已突破2100万元,其 中消炎止咳胶囊和半枝莲胶囊两款主力产品占比过半。 开年的强劲生产势头,源于德良方药业在民族医药领域二十余年的深耕。黔西南素有"天然药库"之称, 公司依托此资源禀赋,将苗族医药验方与现代科技深度融合,打造出半枝莲胶囊、柏花草胶囊等苗药特 色产品,形成显著差异化优势。 "我们构建了'种植-研发-生产-销售'的全产业链模式。"黄河称,近年来公司持续向上游种植和下游销售 延伸,专注研发创新,产品涵盖呼吸系统类、消化系统类、补益类等,目前独家品种数量占比达50%。 "十四五"以来,公司产能从最初的8%左右增长到现在的17%左右,实现翻倍。2026年,公司规划明 确:一 ...
从“土方子”到大产业 四川兴文推动民族医药走出大山
Zhong Guo Xin Wen Wang· 2025-06-13 17:59
Group 1 - The core viewpoint of the articles highlights the successful cultivation of the medicinal herb Epimedium in Longtang Village, Sichuan, which has significantly increased the income of local farmers, doubling their annual earnings per acre [1] - The cultivation of Epimedium has become a leading industry in Longtang Village, benefiting from a cooperative model involving the company, village collective, and farmers, ensuring stable income through contract farming [1] - Sichuan province has over 2,000 types of medicinal resources, with a total medicinal material reserve exceeding 250,000 tons, promoting the development of ethnic medicine as part of a broader strategy for traditional Chinese medicine [2] Group 2 - The Sichuan government has implemented various policies to support the development of ethnic medicine, including the "Sichuan Province Traditional Chinese Medicine Industry Development Plan (2018-2025)" and funding initiatives totaling 32.12 million yuan since 2019 [2] - The ethnic medicine industry in Yibin County is thriving, with a rich variety of medicinal plants and a long history of traditional medicine practices among the local Miao population [5] - The establishment of the Miao Medicine Experience Hall in Yibin County has attracted thousands of visitors, showcasing over 300 types of Miao medicinal herbs and offering immersive experiences related to traditional medicine [5][7] Group 3 - The integration of traditional Miao medicine with modern technology has led to the development of various health and wellness products, enhancing the appeal of ethnic medicine in the market [7] - The diverse and convenient external application methods of Miao medicine make it suitable for all age groups and effective in preventing and treating various diseases, contributing to its market popularity [7] - The potential for ethnic medicine in the health and wellness industry is significant, driven by natural resource advantages and unique cultural characteristics, fostering a competitive market position [7]
西藏利众院:扎根高原,以创新驱动中藏药产业发展
Zhong Guo Chan Ye Jing Ji Xin Xi Wang· 2025-05-30 07:07
Core Insights - The article highlights the growth and development of Tibet Lizhongyuan Biotechnology Co., Ltd. as a leading player in the traditional Tibetan medicine industry, supported by Kunming Pharmaceutical Group since 2010 [1][2]. Group 1: Resource Integration - Tibet Lizhongyuan has established a robust capital and technical support system, with Kunming Pharmaceutical Group holding a 75% stake, allowing for effective integration of high-quality medicinal resources and modern production technologies [2]. - The company has built a complete industry chain from medicinal material cultivation to processing and distribution, benefiting from a favorable corporate tax rate of 15% in Tibet, which helps reduce operational costs [2]. Group 2: Diversified Development - The company has expanded its business into various sectors, including traditional Tibetan medicine, antibiotics, biopharmaceuticals, health products, cosmetics, and beverages, showcasing a diversified development strategy [3]. - Tibet Lizhongyuan is also exploring emerging fields such as ecological tourism and agricultural product trade, enhancing its industry structure and market presence [3]. Group 3: Financial Performance - Financial data indicates that Tibet Lizhongyuan has maintained steady growth, with a revenue of 297 million yuan and a net profit of 3.459 million yuan in the first half of 2019, alongside stable cash flow exceeding 30 million yuan [4]. - As of 2023, the company's asset scale has surpassed 38 million yuan, positioning it as a benchmark enterprise in the Tibetan pharmaceutical sector [4]. Group 4: Heritage and Innovation - The company emphasizes the integration of traditional Tibetan medicine wisdom with modern technology, aiming to create an internationally influential ethnic medicine brand [5]. - Through continuous technological innovation and product upgrades, Tibet Lizhongyuan has launched a series of proprietary Tibetan medicine products, gaining widespread market recognition [5]. - Looking ahead, the company plans to leverage its resource advantages and deepen collaboration with Kunming Pharmaceutical Group to promote high-quality development in the Tibetan medicine industry [5].